Travere Therapeutics Announces Completion of Patient Enrollment in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
November 30, 2020 16:05 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced completion of patient enrollment in the Phase 3 DUPLEX Study. The pivotal DUPLEX Study is evaluating...
Retrophin Announces Corporate Name Change to Travere Therapeutics, Inc.
November 16, 2020 08:00 ET
|
Retrophin, Inc.
New name reflects dedication to patient-inspired mission of identifying, developing and delivering life-changing rare disease therapies Company’s shares to trade under new ticker symbol TVTX on...
Retrophin to Present at Upcoming Investor Conferences
November 11, 2020 16:30 ET
|
Retrophin, Inc.
SAN DIEGO, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Company management will present at the following upcoming virtual investor conferences in November...
Retrophin Reports Third Quarter 2020 Financial Results
November 05, 2020 16:01 ET
|
Retrophin, Inc.
Pivotal DUPLEX Study of sparsentan in FSGS nears completion of enrollment; topline proteinuria data expected 1Q21 Pivotal PROTECT Study achieved enrollment of 280th patient with IgAN to enable...
Retrophin to Report Third Quarter 2020 Financial Results
October 21, 2020 16:30 ET
|
Retrophin, Inc.
SAN DIEGO, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report third quarter 2020 financial results on Thursday, November 5, 2020 after the close of the...
Retrophin Announces Presentation of Abstracts at ASN Kidney Week 2020 Reimagined
October 09, 2020 16:01 ET
|
Retrophin, Inc.
SAN DIEGO, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that it will present new data from a post-hoc analysis examining the proportion of patients with focal...
Retrophin Announces Enrollment of First 280 Patients in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy
September 21, 2020 08:00 ET
|
Retrophin, Inc.
SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that the first 280 patients have been enrolled in the pivotal Phase 3 PROTECT Study evaluating the safety...
Retrophin Reports Second Quarter 2020 Financial Results
July 30, 2020 16:01 ET
|
Retrophin, Inc.
Enrollment ahead of schedule in Phase 3 PROTECT Study of sparsentan in IgAN; topline proteinuria data from both pivotal studies in FSGS and IgAN now anticipated in 2021 Net product sales increased...
Retrophin to Report Second Quarter 2020 Financial Results
July 16, 2020 16:30 ET
|
Retrophin, Inc.
SAN DIEGO, July 16, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report second quarter 2020 financial results on Thursday, July 30, 2020 after the close of the...
Retrophin to Present at the BMO 2020 Prescriptions for Success Healthcare Conference
June 19, 2020 08:00 ET
|
Retrophin, Inc.
SAN DIEGO, June 19, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube, Ph.D., chief executive officer, will present at the BMO 2020 Prescriptions for Success...